CURX
NASDAQCuranex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc (CURX) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 2 wire items for CURX, including 2 SEC filings. The most recent was published Oct 19, 2026.
Financial highlights
Full financials- Net income, TTM
- -$10.47M
- Cash
- $2.94M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks9+100%
2026-05-102026-11-01
Mix490d
- SEC Filings4(100%)
Latest news
25 items- SECSEC Form S-8 filed by Curanex Pharmaceuticals IncS-8 - Curanex Pharmaceuticals Inc (0002025942) (Filer)
- SECSEC Form 8-K filed by Curanex Pharmaceuticals Inc8-K - Curanex Pharmaceuticals Inc (0002025942) (Filer)
- SECCuranex Pharmaceuticals Inc filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Curanex Pharmaceuticals Inc (0002025942) (Filer)
- SECSEC Form 10-Q filed by Curanex Pharmaceuticals Inc10-Q - Curanex Pharmaceuticals Inc (0002025942) (Filer)
- SECSEC Form S-8 filed by Curanex Pharmaceuticals IncS-8 - Curanex Pharmaceuticals Inc (0002025942) (Filer)
- SECSEC Form DEF 14C filed by Curanex Pharmaceuticals IncDEF 14C - Curanex Pharmaceuticals Inc (0002025942) (Filer)
- SECSEC Form PRE 14C filed by Curanex Pharmaceuticals IncPRE 14C - Curanex Pharmaceuticals Inc (0002025942) (Filer)
- SECCuranex Pharmaceuticals Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Curanex Pharmaceuticals Inc (0002025942) (Filer)
- SECSEC Form 10-Q filed by Curanex Pharmaceuticals Inc10-Q - Curanex Pharmaceuticals Inc (0002025942) (Filer)
- SECCuranex Pharmaceuticals Inc filed SEC Form 8-K: Other Events8-K - Curanex Pharmaceuticals Inc (0002025942) (Filer)
- PRCuranex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic DeclineExpanded case series includes advanced thymic carcinoma, small cell lung cancer, pancreatic cancer, end-stage liver cirrhosis, and end-stage renal disease According to patient accounts, multiple critically ill patients with very poor prognoses reported meaningful improvements in functional status, appetite, mobility, and overall condition after taking the Company's product Jericho, New York, April 08, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (NASDAQ:CURX) ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today highlighted five additional patient cases that mana
- PRCuranex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive CareCase involving senior dosimetrist at a premier cancer hospital in the Northeast suggests potential relevance of Phyto-N in one of oncology's most serious and underserved supportive-care markets Jericho, New York, April 06, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (NASDAQ:CURX) ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today highlighted a patient case study that management believes further supports the Company's strategic interest in treatment of cancer cachexia, a serious cancer-associated wasting syndrome marked by progressive weight loss, muscle deplet
- SECCuranex Pharmaceuticals Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Curanex Pharmaceuticals Inc (0002025942) (Filer)
- SECSEC Form 10-K filed by Curanex Pharmaceuticals Inc10-K - Curanex Pharmaceuticals Inc (0002025942) (Filer)
- PRCuranex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND SubmissionPhyto-N 28-Day Repeat-Dose Study in Rats and Dogs Shows No Findings of Toxicological Significance at Maximum Feasible Dose, Enabling Advancement to GLP Toxicology Program Jericho, New York, March 18, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (NASDAQ:CURX) ("Curanex" or the "Company"), a development-stage pharmaceutical company focused on the discovery and development of botanical drugs for inflammatory diseases, today announced the successful completion of a dose-range finding toxicology study of its lead botanical drug candidate, Phyto-N, conducted in Sprague-Dawley rats and dogs. The study evaluated repeat-dose oral tolerability over 28 days and is designed to inform dose s
- PRCuranex Expands Scientific Advisory Board With Two Distinguished ResearchersNew Appointments Bring Deep Expertise in Immunology and Infectious Disease to Advance IND Submission and Intellectual Property Strategy Jericho, New York, March 12, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (NASDAQ:CURX) ("Curanex" or the "Company"), a development-stage pharmaceutical company focused on the discovery and development of botanical drugs for the treatment of inflammatory diseases, today announced the appointment of two highly respected and accomplished life sciences research experts to the Company's Scientific Advisory Board. Dr. Taku Kambayashi and Dr. Selvakumar Subbian bring world-class expertise in immunology and infectious disease, directly aligned with the
- PRCuranex Appoints Two Veteran Industry Leaders to Scientific Advisory BoardNew Advisors Bring 50+ Years of Leadership Experience With 2 of the Top 10 Global Pharmaceuticals Companies Jericho, New York, March 11, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (NASDAQ:CURX) ("Curanex" or the "Company"), a development-stage pharmaceutical company focused on the discovery and development of botanical drugs for the treatment of inflammatory diseases, today announced the appointment of two highly respected and accomplished life sciences research experts to the Company's Scientific Advisory Board. Together, Dr. Daniel Pascheles and Dr. Nicholas A. Meanwell have contributed more than 75 years of total pharmaceuticals experience, including a combined 50 years at M
- SECCuranex Pharmaceuticals Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits8-K - Curanex Pharmaceuticals Inc (0002025942) (Filer)
- PRCuranex Forms World Class Scientific Advisory BoardBoard Includes Former Fortune 100 Pharma Executive and Leading US Medical Research Academic Jericho, New York, March 05, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (NASDAQ:CURX) ("Curanex" or the "Company"), a development-stage pharmaceutical company focused on the discovery and development of botanical drugs for the treatment of inflammatory diseases, today announced the formation of a new Scientific Advisory Board, reporting to and supporting the executive team and Board of Directors of Curanex. The purpose of this Scientific Advisory Board will be two-fold. First, the Advisory Board will support all research and development, including upcoming clinical trials, technical sup
- PRCuranex Provides Operational Update on Key Regulatory MilestonesCompany Completes GMP Pilot for Phyto-N, Targets Ulcerative Colitis IND Submission Q4 2026 Jericho, New York, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (NASDAQ:CURX) ("Curanex" or the "Company"), a development-stage pharmaceutical company focused on the discovery and development of botanical drugs for the treatment of inflammatory diseases, today announced the completion of a Good Manufacturing Practice (GMP)-compliant pilot-scale batch of its lead botanical drug candidate, Phyto-N. This pilot marks a key manufacturing milestone in preparation for its planned Investigational New Drug (IND) submission for ulcerative colitis. Since completing its initial public offerin
- SECCuranex Pharmaceuticals Inc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Curanex Pharmaceuticals Inc (0002025942) (Filer)
- SECSEC Form 10-Q filed by Curanex Pharmaceuticals Inc10-Q - Curanex Pharmaceuticals Inc (0002025942) (Filer)
- SECSEC Form NT 10-Q filed by Curanex Pharmaceuticals IncNT 10-Q - Curanex Pharmaceuticals Inc (0002025942) (Filer)
- SECCuranex Pharmaceuticals Inc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Curanex Pharmaceuticals Inc (0002025942) (Filer)
- PRCuranex Pharmaceuticals Inc. Engages Strategic Investor Relations to Enhance Investor Communications and EngagementJericho, New York, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (NASDAQ:CURX) ("Curanex" or the "Company"), a developmental-stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases, has engaged Strategic Investor Relations, LLC, a premier investor relations firm, to enhance Curanex's visibility in the financial community and support its ongoing efforts to engage and educate current and potential investors about the Company's innovative pipeline and strategic initiatives. With this new partnership, Curanex aims to refine its communication strategies and investor relations activities to ensure stakeholders are fully infor
CURX FAQ
8 questionsWhat is the latest news on CURX?
In the last 30 days Quantisnow tracked 2 wire items for CURX: 2 SEC filings. The most recent was published on October 19, 2026.Is CURX profitable?
No. Curanex Pharmaceuticals Inc reported a net loss of $10.47M for the twelve months ended Jun 30, 2026.How much cash and debt does CURX have?
Curanex Pharmaceuticals Inc reported $2.94M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does CURX stock trade?
Curanex Pharmaceuticals Inc (CURX) is listed on NASDAQ.What sector and industry is CURX in?
Curanex Pharmaceuticals Inc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Curanex Pharmaceuticals Inc go public?
Curanex Pharmaceuticals Inc (CURX) completed its IPO in 2025.What companies are similar to CURX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CURX side-by-side with any of them on Quantisnow.How can I track CURX on Quantisnow?
Quantisnow aggregates Curanex Pharmaceuticals Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CURX to receive live email and push alerts on every new disclosure.